Compare abrdn Physical Palladium Shares ETF (PALL) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Physical Palladium Shares ETF vs Sanofi SA — how do they compare? abrdn Physical Palladium Shares ETF trades at $20.77 (market cap $586.03M), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 162.4× abrdn Physical Palladium Shares ETF's market cap, and Sanofi SA pays a 6.01% dividend while abrdn Physical Palladium Shares ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold abrdn Physical Palladium Shares ETF for 33 Days and Sanofi SA for 94 Days on average.
| PALL | SNY | |
|---|---|---|
Market Cap | $586.03M | $95.18B |
Volume | 1,257,028 | 2,995,646 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $37.18 | $52.34 |
52-Week Low | $20.30 | $39.51 |
Typical Hold Time | 33 Days | 94 Days |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PALL trades at $20.77, up 2.32% today, but technical indicators show a bearish trend with moving averages unanimously negative. The ETF faces fundamental data gaps in valuation and profitability metrics. Recent news highlights palladium's underperformance versus other precious metals, with some analysts seeing current price weakness as a buying opportunity given supply risks and industrial demand potential.
The outlook remains cautious with strong bearish technical signals offset by potential catch-up trade opportunities. Key risks include commodity price volatility and industrial demand fluctuations, while potential upside depends on palladium market dynamics reversing recent weakness.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Physical Palladium Shares ETF
PALL is a physically-backed ETF that tracks the spot price of palladium. It holds physical bullion in secure vaults, offering a liquid way to invest in this precious metal primarily used in automotive catalytic converters and electronics.
Read more on PALL →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
